Abstract
An analysis of 51 patients with Parkinsonism who have developed L-dopa induced dyskinesias is presented. The cause has not been proven, although various hypotheses are discussed. One third of the total number of patients treated developed dyskinesia. These patients tend to respond better to L-dopa than the other group. There is a tendency for the older patient or the patient with long-standing disease to develop dyskinesias. There appears to be no way of predicting which patients will develop dyskinesia by analysis of the symptoms or the aetiology of the Parkinsonism syndrome. The unilateral characteristic of the dyskinesia in patients with hemi-Parkinsonism and patients with unilateral thalamotomies suggests that structural abnormalities are critical in determining the presence and localization of dyskinesias. This is supported by non-occurrence of similarly treated patients without Parkinsonism.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bartholini G., Da Prada M., Pletscher A. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J Pharm Pharmacol. 1968 Mar;20(3):228–229. doi: 10.1111/j.2042-7158.1968.tb09726.x. [DOI] [PubMed] [Google Scholar]
- Cotzias G. C., Papavasiliou P. S., Fehling C., Kaufman B., Mena I. Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med. 1970 Jan 1;282(1):31–33. doi: 10.1056/NEJM197001012820107. [DOI] [PubMed] [Google Scholar]
- Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
- Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
- Ernst A. M. Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia. 1965 May 21;7(6):391–399. doi: 10.1007/BF00402361. [DOI] [PubMed] [Google Scholar]
- Ernst A. M. Relation between the structure of certain methoxyphenylethylaminederivatives and the occurrence of a hypokinetic rigid syndrome. Psychopharmacologia. 1965 May 21;7(6):383–390. doi: 10.1007/BF00402360. [DOI] [PubMed] [Google Scholar]
- Ernst A. M., Smelik P. G. Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats. Experientia. 1966 Dec 15;22(12):837–838. doi: 10.1007/BF01897450. [DOI] [PubMed] [Google Scholar]
- Mones R. J., Elizan T. S. A hort-term evaluation of L-dopa therapy in 34 patients with parkinsonism. J Mt Sinai Hosp N Y. 1969 Nov-Dec;36(6):503–515. [PubMed] [Google Scholar]
- Mones R. J., Elizan T. S., Siegel G. J. Evaluation of L-dopa therapy in Parkinson's disease. N Y State J Med. 1970 Sep 15;70(18):2309–2318. [PubMed] [Google Scholar]
- Poirier L. J., Sourkes T. L., Bouvier G., Boucher R., Carabin S. Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain. 1966 Mar;89(1):37–52. doi: 10.1093/brain/89.1.37. [DOI] [PubMed] [Google Scholar]
- Sourkes T. L., Poirier L. J. Serotonin and dopamine in the extrapyramidal system. Adv Pharmacol. 1968;6(Pt A):335–346. doi: 10.1016/s1054-3589(08)61189-8. [DOI] [PubMed] [Google Scholar]
- Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]